Medpace CEO sells 11,824 shares of stock
Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Common Stock totaling 11,824 shares over two days in August 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Medpace Holdings, Inc. President & CEO August J. Troendle reported open-market sales of Common Stock totaling 11,824 shares over two days in August 2026. He sold 11,366 shares on August 12, 2026 at a weighted average price of $601.53 per share and 458 shares on August 13, 2026 at a weighted average price of $600.39 per share, both effected pursuant to a limit order during an open window period. The filing also reports 4,733,019 shares of Common Stock held indirectly through Medpace Investors, LLC, for which Troendle is the sole manager with voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Insider Trade Summary
Net Seller: 11,824 shares
Net Sell
3 txns
Insider
Troendle August J.
Role
President & CEO
Sold
11,824 shs ($7.11M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F3 | 458 | $600.39 | $275K |
| Sale | Common Stock F1, F2 | 11,366 | $601.53 | $6.84M |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 603,978 shares (Direct);
Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)
Footnotes (4)
- F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
- F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $603.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.345 to $600.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Key Figures
Shares sold 2026-08-12: 11,366 shares at $601.53 per share
Shares sold 2026-08-13: 458 shares at $600.39 per share
Total shares sold: 11,824 shares
+3 more
6 metrics
Shares sold 2026-08-12
11,366 shares at $601.53 per share
Open-market sale of Common Stock on August 12, 2026
Shares sold 2026-08-13
458 shares at $600.39 per share
Open-market sale of Common Stock on August 13, 2026
Total shares sold
11,824 shares
Aggregate of reported Common Stock sales in August 2026
Indirectly held shares
4,733,019 shares
Common Stock held indirectly via Medpace Investors, LLC as of August 12, 2026
Sale price range 2026-08-12
$600.00 to $603.64
Multiple transactions underlying weighted average price of $601.53
Sale price range 2026-08-13
$600.345 to $600.47
Multiple transactions underlying weighted average price of $600.39
Key Terms
limit order, weighted average price, indirectly beneficially own, pecuniary interest
4 terms
limit order market
"transactions were effected pursuant to a limit order placed by the Reporting Person"
A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.
weighted average price financial
"The reported price is a weighted average price. These shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirectly beneficially own financial
"may be deemed to indirectly beneficially own the securities of the Issuer held by MPI"
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did MEDP CEO August J. Troendle report in this Form 4?
August J. Troendle reported two open-market sales of Medpace Holdings Common Stock totaling 11,824 shares on August 12–13, 2026. The trades were executed pursuant to a limit order during an open trading window.
What indirect Medpace (MEDP) holdings are reported for the CEO?
The filing lists 4,733,019 shares of Medpace Common Stock held indirectly through Medpace Investors, LLC. August J. Troendle manages this entity and has voting and investment control, while disclaiming beneficial ownership beyond his pecuniary interest.
Were the MEDP CEO’s sales under a limit order or trading plan?
The footnotes state the transactions were effected pursuant to a limit order placed during an open window period. The Form 4 does not describe these trades as being executed under a Rule 10b5-1 trading plan.
How are the MEDP CEO’s reported sale prices described?
Each sale’s reported price is a weighted average price. The August 12 trades ranged from $600.00 to $603.64, and the August 13 trades ranged from $600.345 to $600.47, with full details available upon request to the issuer or SEC staff.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates